IP Library Granted Patent US 7,777,034
Granted Patent B2
US 7,777,034 · App. 10/996,483 · Granted Aug 17, 2010

Crystalline ammonium salts of rosuvastatin

Assignee: Teva Pharmaceutical Industries Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,777,034
App. No.
10/996,483
Granted
Aug 17, 2010
Kind
B2
Abstract

Provided are alkyl ammonium crystalline salts of rosuvastatin that provide for purification of rosuvastatin and its pharmaceutically acceptable salts.

Claims (9)

1. A crystalline form of rosuvastatin isopropylammonium salt having an X-ray powder diffraction pattern with peaks at 6.2, 18.8, 19.3, 20.6 and 22.3±0.2 deg. 2-theta.

2. The crystalline form of claim 1 , further having peaks at 6.0, 10.2, 10.6, 13.4, 15.6, 16.6, 18.2, 27.3 and 28.8±0.2 deg. 2-theta.

3. The crystalline form of claim 1 , wherein the crystalline form has an X-ray powder diffraction pattern substantially as depicted in FIG. 1 .

4. A process for preparing the crystalline form of claim 1 , said process comprising combining a solution of rosuvastatin acid in an organic solvent with isopropylamine to precipitate the crystalline form and recovering the crystalline form.

5. The process of claim 4 , wherein precipitation is induced by cooling the solution to a temperature of less than about 10° C.

6. The process of claim 4 , wherein the combining is at a temperature of about 20° C. to about 40° C.

7. The process of claim 6 , wherein the temperature is about 30° C.

8. The process of claim 4 , wherein the solvent is acetonitrile or ethyl acetate.

9. A process for preparing the crystalline form of claim 1 , said process comprising combining a solution of rosuvastatin acid in acetonitrile or ethyl acetate with isopropylamine followed by stirring at a temperature of about 30° C., followed by cooling to a temperature of less than about 10° C. to precipitate the crystalline form and recovering the crystalline form.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jul 14, 2010
From: COLUMBIA UNIVERSITY NEW YORK
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024682/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2005
From: CHEN, KOBI
To: TEVA PHARMACEUTICAL INDUSTRIES LTD
Reel/Frame 017019/0463 →
ASSIGNMENT OF RIGHTS IN BARBADOS Recorded Feb 24, 2005
From: TEVA PHARMACEUTICAL INDUSTRIES LTD.
To: TEVA PHARMACEUTICALS USA, INC.
Reel/Frame 015785/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2005
From: NIDDAM-HILDESHEIM, VALERIE; ARONHIME, JUDITH
To: TEVA PHARMACEUTICAL INDUSTRIES LTD.
Reel/Frame 015785/0484 →
Continuity (3)
Provisional Application 6052512800 · Nov 24, 2003
Provisional Application 6053447900 · Jan 5, 2004
Related Publication 20050131066A1 · Jun 16, 2005